DarioHealth Corp. (DRIO)
| Market Cap | 58.40M +100.7% |
| Revenue (ttm) | 21.19M -24.4% |
| Net Income | -44.17M |
| EPS | -8.77 |
| Shares Out | 7.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,871 |
| Open | 8.01 |
| Previous Close | 8.20 |
| Day's Range | 7.86 - 8.28 |
| 52-Week Range | 5.94 - 17.74 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 18.50 (+131.25%) |
| Earnings Date | May 13, 2026 |
About DRIO
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the sympt... [Read more]
Financial Performance
In 2025, DarioHealth's revenue was $22.36 million, a decrease of -17.31% compared to the previous year's $27.04 million. Losses were -$40.31 million, 34.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for DRIO stock is "Buy." The 12-month stock price target is $18.5, which is an increase of 131.25% from the latest price.
News
DarioHealth Q1 Earnings Call Highlights
DarioHealth NASDAQ: DRIO reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital health platform further into care delivery, management said on t...
DarioHealth Earnings Call Transcript: Q1 2026
Sequential revenue growth and reduced operating expenses marked Q1 2026, with expanded channel partnerships and a strong commercial pipeline. Strategic moves into care delivery and outcomes-based models are expected to drive future growth.
DarioHealth Quarterly report: Q1 2026
DarioHealth has published its Q1 2026 quarterly earnings report on May 13, 2026.
DarioHealth Earnings release: Q1 2026
DarioHealth released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
DarioHealth Slides: Q1 2026
DarioHealth has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
DarioHealth reports Q1 EPS ($1.25), consensus (85c)
Reports Q1 revenue $5.58M, consensus $5.46M. “The first quarter of 2026 was our second consecutive quarter of sequential revenue growth, alongside continued reductions in operating expenses. Our chann...
DarioHealth Reports First Quarter 2026 Financial and Operating Results
First quarter 2026 revenues increased to $5.6 million, marking the second consecutive quarter of sequential growth Operating expenses decreased by 21% year-over-year and decreased by 8% quarter-over-q...
DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital ...
Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research
Findings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plans Statistically significant impro...
DarioHealth Slides: Corporate presentation
DarioHealth has posted slides in relation to its latest quarterly earnings report, which was published on April 15, 2026.
Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling
Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize it...
DarioHealth Slides: Corporate presentation
DarioHealth has posted slides in relation to its latest quarterly earnings report, which was published on April 10, 2026.
DarioHealth trading halted, volatility trading pause
12:50 EDT DarioHealth (DRIO) trading halted, volatility trading pause
One new option listing and ten option delistings on March 23rd
New option listings for March 23rd include Roundhill Top Weeklypay Etf (TOPW). Option delistings effective March 23rd include CALVERT US SELECT EQUITY (CVSE), DarioHealth (DRIO), Enlightify Inc (ENFY)...
DarioHealth price target lowered to $10 from $16 at Stifel
Stifel lowered the firm’s price target on DarioHealth (DRIO) to $10 from $16 and keeps a Buy rating on the shares. The firm continues to model 2025 and 2026 revenue…
DarioHealth files $100M mixed securities shelf
17:04 EDT DarioHealth (DRIO) files $100M mixed securities shelf
DarioHealth Earnings Call Transcript: Q4 2025
Record new business wins in 2025 offset a legacy client loss, with Q4 revenue growth and expanding gross margins. Pipeline value surged to $122 million, and cost discipline plus AI efficiencies are expected to drive a 30% reduction in operating loss in 2026, targeting cash flow breakeven by mid-2027.
DarioHealth Earnings release: Q4 2025
DarioHealth released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
DarioHealth Annual report: Q4 2025
DarioHealth has published its Q4 2025 annual report on March 19, 2026.
DarioHealth Registration statement: Registration filing
DarioHealth filed a registration statement on March 19, 2026, providing details about a securities offering with the SEC.
DarioHealth reports Q4 revenue $5.2M, consensus $5.05M
“2025 was our strongest commercial year on record – 85 new agreements signed and contracted and late stage ARR contracts representing $12.9 million are expected to begin converting to revenue…
DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 2025 2025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due...
DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digit...
Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health
Findings reinforce that engagement data provide clinical signals directly impacting ROI Analysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curve...